SUMMARY OF INVENTION
MSK investigators have developed a novel method of imaging tissue in a preclinical or clinical setting to enhance Cerenkov luminescence from radiotracers without increasing radionuclide dose. This method involves coupling a radionuclide to a nanoparticle (i.e. silica nanoparticle or liposome). Since light is refracted from nanoparticles more so than tissue, the resulting Cerenkov light is stronger for radionuclides coupled to nanoparticles, compared to radionuclides alone. By enhancing the brightness and imaging potential, this method will significantly increase the benefits associated with Cerenkov luminescence-oriented systems.
Cerenkov luminescence describes a weak light that is emitted when a particle travels through a medium at a velocity faster than the speed of light travels through the medium. The light emitted from Cerenkov luminescence is weaker in mediums through which light can pass more easily compared to mediums through which light is more refracted.
In medical settings, radionuclides traveling through serum and tissue can produce Cerenkov light. This allows for a radiotracer to be detected with two independent modalities – optical and PET imaging. Advantages of this dual imaging system include that optical cameras are much less expensive than PET imaging instruments, and radionuclides that are difficult to image in vivo could be imaged using Cerenkov luminescence. However, the level of light emitted is low and the detection of Cerenkov luminescence requires a highly sensitive device, thereby limiting the potential applications of this technology in preclinical or clinical settings. This novel method enables a stronger Cerenkov luminescent image than was previously possible.
Proprietary method for enhancing Cerenkov luminescence using nanoparticles
Allows for expanded use of Cerenkov luminescence which will facilitate broader applications of preclinical and clinical imaging
This novel method could expand the benefits and potential use of Cerenkov luminescence for broad applications, including both preclinical and clinical imaging.
STAGE OF DEVELOPMENT
PCT application filed on February 17, 2016
Jan Grimm, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, MSK